Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa

Bone

Volumn 46, Issue 3, 2010, Pages 796-800

  Wojcik, Monica H ^a   Meenaghan, Erinne ^a   Lawson, Elizabeth A ^a   Misra, Madhusmita ^a   Klibanski, Anne ^a   Miller, Karen K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amylin; Anorexia nervosa; Bone mineral density; GIP; GLP2

Indexed keywords

AMYLIN; CARBOXY TERMINAL TELOPEPTIDE; GASTROINTESTINAL POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 2; AMYLOID; BIOLOGICAL MARKER;

ADULT; ANOREXIA NERVOSA; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; FEMUR NECK; HIP; HORMONE BLOOD LEVEL; HUMAN; PREDICTION; SPINE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; BODY MASS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIET; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS); YOUNG ADULT;

ADOLESCENT; ADULT; AMYLOID; ANOREXIA NERVOSA; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY; CROSS-SECTIONAL STUDIES; DIET; FEMALE; HUMANS; YOUNG ADULT; ISLET AMYLOID POLYPEPTIDE;

EID: 77649187443     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.11.014     Document Type: Article

References (55)

1. Grinspoon S., Thomas E., Pitts S., Gross E., Mickley D., Miller K., et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann. Intern. Med. 2000, 133:790-794.
2. Miller K.K., Grinspoon S.K., Ciampa J., Hier J., Herzog D., Klibanski A. Medical findings in outpatients with anorexia nervosa. Arch. Intern. Med. 2005, 165:561-566.
3. Clowes J.A., Khosla S., Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J. Bone Miner. Res. 2005, 20:1497-1506.
4. Clowes J.A., Hannon R.A., Yap T.S., Hoyle N.R., Blumsohn A., Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002, 30:886-890.
5. Cooper G.J., Willis A.C., Clark A., Turner R.C., Sim R.B., Reid K.B. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad Sci. U. S. A. 1987, 84:8628-8632.
6. MacIntyre I. Amylinamide, bone conservation, and pancreatic beta cells. Lancet 1989, 2:1026-1027.
7. Bronsky J., Prusa R., Nevoral J. The role of amylin and related peptides in osteoporosis. Clin. Chim. Acta 2006, 373:9-16.
8. Cornish J., Reid I.R. Effects of amylin and adrenomedullin on the skeleton. J. Musculoskelet Neuronal Interact. 2001, 2:15-24.
9. Cornish J., Callon K.E., Lin C.Q., Xiao C.L., Mulvey T.B., Coy D.H., et al. Dissociation of the effects of amylin on osteoblast proliferation and bone resorption. Am. J. Physiol. 1998, 274:E827-E833.
10. Cornish J., Callon K.E., Cooper G.J., Reid I.R. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem. Biophys. Res. Commun. 1995, 207:133-139.
11. Cornish J., Grey A., Callon K.E., Naot D., Hill B.L., Lin C.Q., et al. Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. Biochem. Biophys. Res. Commun. 2004, 318:240-246.
12. Cornish J., Callon K.E., Lin C.Q., Xiao C.L., Gamble G.D., Cooper G.J., et al. Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. J. Bone Miner. Res. 1999, 14:1302-1309.
13. Villa I., Rubinacci A., Ravasi F., Ferrara A.F., Guidobono F. Effects of amylin on human osteoblast-like cells. Peptides 1997, 18:537-540.
14. Villa I., Dal Fiume C., Maestroni A., Rubinacci A., Ravasi F., Guidobono F. Human osteoblast-like cell proliferation induced by calcitonin-related peptides involves PKC activity. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E627-E633.
15. Villa I., Melzi R., Pagani F., Ravasi F., Rubinacci A., Guidobono F. Effects of calcitonin gene-related peptide and amylin on human osteoblast-like cells proliferation. Eur. J. Pharmacol. 2000, 409:273-278.
16. Zaidi M., Pazianas M., Shankar V.S., Bax B.E., Bax C.M., Bevis P.J., et al. Osteoclast function and its control. Exp. Physiol. 1993, 78:721-739.
17. Alam A.S., Moonga B.S., Bevis P.J., Huang C.L., Zaidi M. Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts. Exp. Physiol. 1993, 78:183-196.
18. Cornish J., Callon K.E., Bava U., Kamona S.A., Cooper G.J., Reid I.R. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 2001, 29:162-168.
19. Dacquin R., Davey R.A., Laplace C., Levasseur R., Morris H.A., Goldring S.R., et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J. Cell Biol. 2004, 164:509-514.
20. Pietschmann P., Farsoudi K.H., Hoffmann O., Klaushofer K., Horandner H., Peterlik M. Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria. Bone 1993, 14:167-172.
21. Davey R.A., Moore A.J., Chiu M.W., Notini A.J., Morris H.A., Zajac J.D. Effects of amylin deficiency on trabecular bone in young mice are sex-dependent. Calcif. Tissue Int. 2006, 78:398-403.
22. Cornish J., Callon K.E., King A.R., Cooper G.J., Reid I.R. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am. J. Physiol. 1998, 275:E694-E699.
23. Koda J.E., Fineman M., Rink T.J., Dailey G.E., Muchmore D.B., Linarelli L.G. Amylin concentrations and glucose control. Lancet 1992, 339:1179-1180.
24. Levin M.E., Boisseau V.C., Avioli L.V. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N. Engl. J. Med. 1976, 294:241-245.
25. Hofbauer L.C., Brueck C.C., Singh S.K., Dobnig H. Osteoporosis in patients with diabetes mellitus. J. Bone Miner. Res. 2007, 22:1317-1328.
26. Hui S.L., Epstein S., Johnston C.C. A prospective study of bone mass in patients with type I diabetes. J. Clin. Endocrinol. Metab. 1985, 60:74-80.
27. Zaidi M., Shankar V.S., Huang C.L., Pazianas M., Bloom S.R. Amylin in bone conservation current evidence and hypothetical Considerations. Trends Endocrinol. Metab. 1993, 4:255-259.
28. Bronsky J., Prusa R. Amylin fasting plasma levels are decreased in patients with osteoporosis. Osteoporos. Int. 2004, 15:243-247.
29. Fehmann H.C., Goke R., Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 1995, 16:390-410.
30. Wallis K., Walters J.R., Forbes A. Review article: glucagon-like peptide 2-current applications and future directions. Aliment. Pharmacol. Ther. 2007, 25:365-372.
31. Henriksen D.B., Alexandersen P., Bjarnason N.H., Vilsboll T., Hartmann B., Henriksen E.E., et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J. Bone Miner. Res. 2003, 18:2180-2189.
32. Holst J.J., Hartmann B., Gottschalck I.B., Jeppesen P.B., Miholic J., Henriksen D.B. Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Scand. J. Gastroenterol. 2007, 42:814-820.
33. Bollag R.J., Zhong Q., Phillips P., Min L., Zhong L., Cameron R., et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000, 141:1228-1235.
34. Zhong Q., Itokawa T., Sridhar S., Ding K.H., Xie D., Kang B., et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E543-E548.
35. Xie D., Zhong Q., Ding K.H., Cheng H., Williams S., Correa D., et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 2007, 40:1352-1360.
36. Xie D., Cheng H., Hamrick M., Zhong Q., Ding K.H., Correa D., et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 2005, 37:759-769.
37. Bollag R.J., Zhong Q., Ding K.H., Phillips P., Zhong L., Qin F., et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol. Cell Endocrinol. 2001, 177:35-41.
38. Henriksen D.B., Alexandersen P., Byrjalsen I., Hartmann B., Bone H.G., Christiansen C., et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004, 34:140-147.
39. Gottschalck I.B., Jeppesen P.B., Hartmann B., Holst J.J., Henriksen D.B. Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand. J. Gastroenterol. 2008, 43:1304-1310.
40. Haderslev K.V., Jeppesen P.B., Hartmann B., Thulesen J., Sorensen H.A., Graff J., et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand. J. Gastroenterol. 2002, 37:392-398.
41. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association. 4th ed. (text revision). Arlington, VA.
42. National Center for Health Statistics (DHEW). Weight by Height and Age for Adults 18-74 Years: United States 1971-1974. In: Vital and Health Statistics, Series II, no. 208, DHHS Publication No. (PHS) 79 1979, Department of Health, Education, and Welfare, Rockville, MD.
43. Utz A.L., Yamamoto A., Hemphill L., Miller K.K. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J. Clin. Endocrinol. Metab. 2008, 93:2507-2514.
44. Utz A.L., Yamamoto A., Sluss P., Breu J., Miller K.K. Androgens may mediate a relative preservation of IGF-I levels in overweight and obese women despite reduced growth hormone secretion. J. Clin. Endocrinol. Metab. 2008, 93:4033-4040.
45. Finkelstein J.S., Klibanski A., Schaefer E.H., Hornstein M.D., Schiff I., Neer R.M. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N. Engl. J. Med. 1994, 331:1618-1623.
46. Mazess R.B., Barden H.S., Bisek J.P., Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am. J. Clin. Nutr. 1990, 51:1106-1112.
47. Grinspoon S.K., Baum H.B., Kim V., Coggins C., Klibanski A. Decreased bone formation and increased mineral dissolution during acute fasting in young women. J. Clin. Endocrinol. Metab. 1995, 80:3628-3633.
48. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., Christiansen C. Mechanism of circadian variation in bone resorption. Bone 2002, 30:307-313.
49. Li F., Muhlbauer R.C. Food fractionation is a powerful tool to increase bone mass in growing rats and to decrease bone loss in aged rats: modulation of the effect by dietary phosphate. J. Bone Miner. Res. 1999, 14:1457-1465.
50. Soyka L.A., Grinspoon S., Levitsky L.L., Herzog D.B., Klibanski A. The effects of anorexia nervosa on bone metabolism in female adolescents. J. Clin. Endocrinol. Metab. 1999, 84:4489-4496.
51. Misra M., Miller K.K., Cord J., Prabhakaran R., Herzog D.B., Goldstein M., et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 2007, 92:2046-2052.
52. Tanaka M., Tatebe Y., Nakahara T., Yasuhara D., Sagiyama K., Muranaga T., et al. Eating pattern and the effect of oral glucose on ghrelin and insulin secretion in patients with anorexia nervosa. Clin. Endocrinol. (Oxf.) 2003, 59:574-579.
53. Tomasik P.J., Sztefko K., Starzyk J., Rogatko I., Szafran Z. Entero-insular axis in children with anorexia nervosa. Psychoneuroendocrinology 2005, 30:364-372.
54. Stock S., Leichner P., Wong A.C., Ghatei M.A., Kieffer T.J., Bloom S.R., et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J. Clin. Endocrinol. Metab. 2005, 90:2161-2168.
55. Tomasik P.J., Sztefko K., Starzyk J. Cholecystokinin, glucose dependent insulinotropic peptide and glucagon-like peptide 1 secretion in children with anorexia nervosa and simple obesity. J. Pediatr. Endocrinol. Metab. 2004, 17:1623-1631.